Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients

2020 ◽  
Vol 55 ◽  
pp. 116-121 ◽  
Author(s):  
Tijana Kovacevic ◽  
Branislava Miljkovic ◽  
Pedja Kovacevic ◽  
Sasa Dragic ◽  
Danica Momcicevic ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Critically Ill ◽  
Drug Monitoring ◽  
Population Pharmacokinetic Model ◽  
Pharmacokinetic Model ◽  
Monitoring Data ◽  
Therapeutic Drug ◽  
Population Pharmacokinetic

Population Pharmacokinetic Model of Carbamazepine Derived from Routine Therapeutic Drug Monitoring Data

2007 ◽  
Vol 29 (6) ◽  
pp. 781-788 ◽  
Author(s):  
Katarina Vučićević ◽  
Branislava Miljković ◽  
Ružica Veličković ◽  
Milena Pokrajac ◽  
Aleš Mrhar ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Population Pharmacokinetic Model ◽  
Pharmacokinetic Model ◽  
Monitoring Data ◽  
Therapeutic Drug ◽  
Population Pharmacokinetic ◽  
Routine Therapeutic Drug Monitoring

scholarly journals Isavuconazole therapeutic drug monitoring associated to a pharmacogenetic exploration is far from being a pharmacologists’ whim

2018 ◽  
Author(s):  
L Darnaud ◽  
F Lamoureux ◽  
C Godet ◽  
S Pontier ◽  
A Debard ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Population Pharmacokinetic Model ◽  
Pharmacokinetic Model ◽  
Pharmacokinetic Profile ◽  
Therapeutic Drug ◽  
Population Pharmacokinetic ◽  
Collect Blood Sample ◽  
High Concentrations ◽  
Toxic Concentrations

ABSTRACTIsavuconazole is a new antifungal prodrug to treat invasive aspergillosis and mucormycosis, theoretically not requiring drug monitoring. However, we reported 4 clinical cases with toxic concentrations. Based on Desai’s population pharmacokinetic model, we estimated patients’ kinetic profile. Clearance was abnormally low, likely related to CYP3A4/5 polymorphisms. Thus, we recommend to collect blood sample just before the first maintenance dose to estimate pharmacokinetic profile and individualized dose. For patients presenting high concentrations, pharmacogenetics can be done.

scholarly journals Using Population Pharmacokinetics To Determine Gentamicin Dosing during Extended Daily Diafiltration in Critically Ill Patients with Acute Kidney Injury

2010 ◽  
Vol 54 (9) ◽  
pp. 3635-3640 ◽  
Author(s):  
Jason A. Roberts ◽  
Jonathan Field ◽  
Adam Visser ◽  
Rosemary Whitbread ◽  
Mandy Tallot ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Monte Carlo ◽  
Monte Carlo Simulations ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Population Pharmacokinetic Model ◽  
Pharmacokinetic Model ◽  
Kidney Injury ◽  
Therapeutic Drug ◽  
Population Pharmacokinetic

ABSTRACT The objective of the present prospective pharmacokinetic study was to describe the variability of plasma gentamicin concentrations in critically ill patients with acute kidney injury (AKI) necessitating extended daily diafiltration (EDD-f) using a population pharmacokinetic model and to subsequently perform Monte Carlo dosing simulations to determine which dose regimen achieves the pharmacodynamic targets the most consistently. We collected data from 28 gentamicin doses in 14 critically ill adult patients with AKI requiring EDD-f and therapeutic gentamicin. Serial plasma samples were collected. A population pharmacokinetic model was used to describe the pharmacokinetics of gentamicin and perform Monte Carlo simulations with doses of between 3 mg/kg of body weight and 7 mg/kg and at various time points before commencement of EDD-f to evaluate the optimal dosing regimen for achieving pharmacodynamic targets. A two-compartment pharmacokinetic model adequately described the gentamicin clearance while patients were on and off EDD-f. The plasma half-life of gentamicin during EDD-f was 13.8 h, whereas it was 153.4 h without EDD-f. Monte Carlo simulations suggest that dosing with 6 mg/kg every 48 h either 30 min or 1 h before the commencement of EDD-f results in 100% attainment of the target maximum concentration drug in plasma (<10 mg/liter) and sufficient attainment of the target area under the concentration-time curve from 0 to 24 h (AUC0-24; 70 to 120 mg·h/liter). None of the simulated dosing regimens satisfactorily achieved the targets of the minimum concentrations of drug in plasma (<1.0 mg/liter) at 24 h. In conclusion, dosing of gentamicin 30 min to 1 h before the commencement of an EDD-f treatment enables attainment of target peak concentrations for maximal therapeutic effect while enhancing drug clearance to minimize toxicity. Redosing in many patients should occur after 48 h, and we recommend the use of therapeutic drug monitoring to guide dosing to optimize achievement of the AUC0-24 targets.

Sign in / Sign up

Export Citation Format

Share Document